GLUT6 was found to be overexpressed in endometrial cancers by about 37-fold compared to healthy tissue, and GLUT6 knockdown resulted in cell death, an indication that GLUT6 plays a critical role in the growth and metastasis of this cancer and would be an attractive therapeutic target. The gene discussed is SLC2A6; the disease is cancer.